Liquidia Announces Notice of Allowance for U.S. Patent Application Covering Methods of Treating Pulmonary Hypertension with D...
August 28 2020 - 6:15AM
Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical
biopharmaceutical company focused on the development and
commercialization of novel products using its proprietary
PRINT® technology, today announced that it has received a
Notice of Allowance from the U.S. Patent and Trademark Office
(USPTO) for patent application No. 16/099,135 related to LIQ861,
the Company’s proprietary dry powder treprostinil currently under
review with the U.S. Food and Drug Administration (FDA) for the
treatment of pulmonary arterial hypertension (PAH). The patent is
expected to cover methods of treating patients with pulmonary
hypertension through the inhalation of dry powder treprostinil.
“The allowance of this patent will substantially strengthen and
extend our intellectual property position with respect to dry
powder inhaled treprostinil and represents an important milestone
for LIQ861 on its path to potential commercialization. It also
provides further evidence to support the novel advantages of our
proprietary PRINT technology in therapeutic development,” commented
Neal Fowler, Chief Executive Officer of Liquidia. “LIQ861 has the
potential to address a significant unmet need for PAH patients
seeking effective and convenient dosing of inhaled treprostinil. We
are thrilled to have received this patent allowance for methods of
treating patients with inhaled dry powder treprostinil, an
essential step in creating value for our stockholders.”
A Notice of Allowance is issued after the USPTO determines that
a patent should be granted from a patent application. The patent,
which is expected to be issued in the fourth quarter of 2020,
should have a term that expires no earlier than 2037. After
issuance, Liquidia plans to list the U.S. patent in the FDA's
Approved Drug Products with Therapeutic Equivalence Evaluations,
commonly referred to as the “Orange Book”, for LIQ861, if
approved.
About LiquidiaLiquidia is a
late-stage clinical biopharmaceutical company focused on the
development and commercialization of novel products using its
proprietary PRINT® technology to transform the lives of patients.
PRINT is a particle engineering platform that enables precise
production of uniform drug particles designed to improve the
safety, efficacy and performance of a wide range of therapies.
Currently, Liquidia is focused on the development of two
product candidates for which it holds worldwide commercial rights:
LIQ861 for the treatment of pulmonary arterial hypertension (PAH)
and LIQ865 for the treatment of local post-operative
pain. Liquidia is headquartered in Research Triangle
Park, NC. For more information, please
visit www.liquidia.com.
Cautionary Statements Regarding Forward-Looking
Statements
This press release may include forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release other than
statements of historical facts, including statements regarding our
future results of operations and financial position, our strategic
and financial initiatives, our business strategy and plans and our
objectives for future operations, are forward-looking statements.
Such forward-looking statements, including statements regarding
clinical trials, clinical studies and other clinical work
(including the funding therefor, anticipated patient enrollment,
safety data, study data, trial outcomes, timing or associated
costs), regulatory applications and related timelines, including
potential U.S. Food and Drug Administration (FDA)
approval of the New Drug Application (NDA) for LIQ861, the timeline
or outcome related to our patent litigation pending in the U.S.
District Court for the District of Delaware or two petitions
for inter partes review with the Patent Trial and Appeal
Board, the issuance of patents by the USPTO and our ability to
execute on our strategic or financial initiatives, involve
significant risks and uncertainties and actual results could differ
materially from those expressed or implied herein. The words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,”
“intend,” “may,” “plan,” “potential,” “predict,” “project,”
“should,” “target,” “would,” and similar expressions are intended
to identify forward-looking statements. We have based these
forward-looking statements largely on our current expectations and
projections about future events and financial trends that we
believe may affect our financial condition, results of operations,
business strategy, short-term and long-term business operations and
objectives and financial needs. These forward-looking statements
are subject to a number of risks discussed in our and Liquidia
Corporation’s filings with the Securities and Exchange
Commission, including the risk that our proposed acquisition
of RareGen, LLC is not consummated or that the expected
benefits and synergies from the proposed acquisition are not
realized, the impact of the coronavirus (COVID-19) outbreak on our
company and our financial condition and results of operations, as
well as a number of uncertainties and assumptions. Moreover, we
operate in a very competitive and rapidly changing environment and
our industry has inherent risks. New risks emerge from time to
time. It is not possible for our management to predict all risks,
nor can we assess the impact of all factors on our business or the
extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any
forward-looking statements we may make. In light of these risks,
uncertainties and assumptions, the future events discussed in this
press release may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. Nothing in this press release should be
regarded as a representation by any person that these goals will be
achieved, and we undertake no duty to update our goals or to update
or alter any forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact Information Media:
Michael Parks Corporate Communications 484.356.7105
michael.parks@liquidia.com
Investors: Jason Adair Vice President,
Corporate Development and Strategy 919.328.4400
jason.adair@liquidia.com
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From Apr 2024 to May 2024
Liquidia (NASDAQ:LQDA)
Historical Stock Chart
From May 2023 to May 2024